TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Stock analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of TScan Therapeutics in a research report issued on Wednesday, May 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.87) EPS, FY2028 earnings at ($0.80) EPS, FY2029 earnings at ($0.50) EPS and FY2030 earnings at ($0.07) EPS.
Several other analysts also recently issued reports on TCRX. Wall Street Zen downgraded shares of TScan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Wedbush boosted their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Thursday, March 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.00.
TScan Therapeutics Price Performance
Shares of NASDAQ:TCRX opened at $1.21 on Friday. The company’s fifty day moving average is $1.11 and its two-hundred day moving average is $1.15. The company has a quick ratio of 8.41, a current ratio of 8.41 and a debt-to-equity ratio of 0.26. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.57. The company has a market cap of $68.85 million, a P/E ratio of -1.26 and a beta of 1.06.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 84.02%. The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million.
Hedge Funds Weigh In On TScan Therapeutics
Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of TScan Therapeutics in the second quarter worth $309,000. Goldman Sachs Group Inc. increased its stake in shares of TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after acquiring an additional 9,676 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in shares of TScan Therapeutics by 35.7% in the second quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company’s stock worth $223,000 after acquiring an additional 40,400 shares during the last quarter. XTX Topco Ltd increased its stake in shares of TScan Therapeutics by 1,142.5% in the fourth quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock worth $219,000 after acquiring an additional 201,375 shares during the last quarter. Finally, Militia Capital Partners LP acquired a new position in shares of TScan Therapeutics in the second quarter worth $137,000. 82.83% of the stock is owned by institutional investors and hedge funds.
TScan Therapeutics Company Profile
TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.
The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.
Further Reading
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
